Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
Insider & Institutional Ownership
58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Scinai Immunotherapeutics and Adaptimmune Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scinai Immunotherapeutics | N/A | N/A | -30.48% |
| Adaptimmune Therapeutics | -25.43% | -74.15% | -15.09% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scinai Immunotherapeutics | $452,000.00 | 6.58 | -$6.50 million | ($239.17) | -0.01 |
| Adaptimmune Therapeutics | $175.04 million | 0.88 | -$113.87 million | ($0.22) | -2.72 |
Scinai Immunotherapeutics has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations for Scinai Immunotherapeutics and Adaptimmune Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scinai Immunotherapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Adaptimmune Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Adaptimmune Therapeutics has a consensus target price of $2.79, suggesting a potential upside of 365.05%. Given Adaptimmune Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Scinai Immunotherapeutics.
Risk and Volatility
Scinai Immunotherapeutics has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.
Summary
Scinai Immunotherapeutics beats Adaptimmune Therapeutics on 8 of the 14 factors compared between the two stocks.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
